NCT02947685
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 3
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients must also have tumors that are either ER+ or PR+
Exclusions: Participants with history of treated CNS metastases are eligible, but must meet certain criteria- see trial for details
https://ClinicalTrials.gov/show/NCT02947685